Metabolic remodelling of the failing heart: Beneficial or detrimental?

Cardiovascular Research

Volumn 81, Issue 3, 2009, Pages 420-428

  Van Bilsen, Marc ^a   Van Nieuwenhoven, Frans A ^a   Van Der Vusse, Ger J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Energy metabolism; Fatty acids; Glucose; Hypertrophy; Mitochondria; Peroxisome proliferator activated receptor

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; ACETIC ACID C 11; ADENOSINE TRIPHOSPHATE; CARBOHYDRATE; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; CD36 ANTIGEN; ETOMOXIR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE C 11; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; LIPID; LONG CHAIN FATTY ACID COENZYME A LIGASE; MESSENGER RNA; PALMITIC ACID C 11; PERHEXILINE; RANOLAZINE; TRACER; TRIMETAZIDINE; UNCLASSIFIED DRUG;

CARBOHYDRATE METABOLISM; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG UPTAKE; ENERGY CONVERSION; ENERGY METABOLISM; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; HEART FAILURE; HEART HYPERTROPHY; HEART MITOCHONDRION; HEART MUSCLE METABOLISM; HEART MUSCLE POTENTIAL; HIGH ENERGY PHOSPHATE; HUMAN; LIPID METABOLISM; METABOLIC ACTIVATION; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXYGEN CONSUMPTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADAPTATION, PHYSIOLOGICAL; ADENOSINE TRIPHOSPHATE; ANIMALS; CARDIOMEGALY; ENERGY METABOLISM; FATTY ACIDS; GLUCOSE; HEART FAILURE; HUMANS; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; MYOCARDIUM; OXIDATION-REDUCTION; VENTRICULAR REMODELING;

EID: 59449110495     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn282     Document Type: Review

References (101)

1. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol 2004;555:1-13.
2. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129.
3. van Bilsen M, Smeets PJH, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res 2004;61:218-226.
4. Ingwall JS, Weiss RG. Is the failing heart energy starved?: on using chemical energy to support cardiac function. Circ Res 2004;95:135-145.
5. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007;356:1140-1151.
6. van Bilsen M, van der Vusse GJ, Reneman RS. Transcriptional regulation of metabolic processes: implications for cardiac metabolism. Pflügers Arch 1998;437:2-14.
7. van der Vusse GJ, Glatz JFC, Stam HCG, Reneman RS. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 1992;72:881-940.
8. Teusink B, Voshol PJ, Dahlmans VEH, Rensen PCN, Pijl H, Romijn JA et al. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes 2003;52:614-620.
9. Augustus AS, Kako Y, Yagyu H, Goldberg IJ. Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab 2003;284:E331-E339.
10. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 1994;267:H742-H750.
11. Young ME, Laws FA, Goodwin GW, Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 2001;276:44390-44395.
12. How O-J, Aasum E, Kunnathu S, Severson DL, Myhre ESP, Larsen TS. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts. Am J Physiol Heart Circ Physiol 2005;288:H2979-H2985.
13. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 1998;83:969-979.
14. Neglia D, De Caterina A, Marraccini P, Natali A, Ciardetti M, Vecoli C et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2007;293:H3270-H3278.
15. Garnier A, Fortin D, Delomenie C, Momken I, Veksler V, Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 2003;551:491-501.
16. Sharov VG, Todor AV, Silverman N, Goldstein S, Sabbah HN. Abnormal mitochondrial respiration in failed human myocardium. J Mol Cell Cardiol 2000;32:2361-2367.
17. Degens H, de Brouwer K, Gilde A, Lindhout M, Willemsen P, Janssen B et al. Cardiac fatty acid metabolism is preserved in the compensated hypertrophic rat heart. Basic Res Cardiol 2006;101:17-26.
18. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-[delta] deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004;10:1245-1250.
19. Fischer Y, Thomas J, Sevilla L, Munoz P, Becker C, Holman G et al. Insulin-induced recruitment of glucose transporter 4 (GLUT4) and GLUT1 in isolated rat cardiac myocytes. J Biol Chem 1997;272:7085-7092.
20. Barth E, Stämmler G, Speiser B, Schaper J. Ultrastructural quantification of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. J Mol Cell Cardiol 1992;24:669-681.
21. Sanbe A, Tanonaka K, Kobayasi R, Takeo S. Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol 1995;27:2209-2222.
22. Javadov S, Huang C, Kirshenbaum L, Karmazyn M. NHE-1 inhibition improves impaired mitochondrial permeability transition and respiratory function during postinfarction remodelling in the rat. J Mol Cell Cardiol 2005;38:135-143.
23. Rosca MG, Vazquez EJ, Kerner J, Parland W, Chandler MP, Stanley W et al. Cardiac mitochondria in failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res 2008;80:30-39.
24. Kalsi KK, Smolenski RT, Pritchard RD, Khaghani A, Seymour AM, Yacoub MH. Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy. Eur J Clin Invest 1999;29:469-477.
25. Ide T, Tsutsui H, Hayashidani S, Kang D, Suematsu N, Nakamura K et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001;88:529-535.
26. Scheubel RJ, Tostlebe M, Simm A, Rohrbach S, Prondzinsky R, Gellerich FN et al. Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. J Am Coll Cardiol 2002;40:2174-2181.
27. Javadov S, Purdham DM, Zeidan A, Karmazyn M. NHE-1 inhibition improves cardiac mitochondrial function through regulation of mitochondrial biogenesis during postinfarction remodeling. Am J Physiol Heart Circ Physiol 2006;291:H1722-H1730.
28. El Alaoui-Talibi Z, Landormy S, Loireau A, Moravec J. Fatty acid oxidation and mechanical performance of volume-overloaded rat hearts. Am J Physiol 1992;262:H1068-H1074.
29. Baudet S, Kuznetsov A, Merciai N, Gorza L, Ventura-Clapier R. Biochemical, mechanical and energetic characterization of right ventricular hypertrophy in the ferret heart. J Mol Cell Cardiol 1994;26:1573- 1586.
30. Bugger H, Chemnitius J-M, Doenst T. Differential changes in respiratory capacity and ischemia tolerance of isolated mitochondria from atrophied and hypertrophied hearts. Metabolism 2006;55:1097-1106.
31. Murray AJ, Cole MA, Lygate CA, Carr CA, Stuckey DJ, Little SE et al. Increased mitochondrial uncoupling proteins, respiratory uncoupling and decreased efficiency in the chronically infarcted rat heart. J Mol Cell Cardiol 2008;44:694-700.
32. Liu J, Wang C, Murakami Y, Gong G, Ishibashi Y, Prody C et al. Mitochondrial ATPase and high-energy phosphates in failing hearts. Am J Physiol Heart Circ Physiol 2001;281:H1319-H1326.
33. Gong G, Liu J, Liang P, Guo T, Hu Q, Ochiai K et al. Oxidative capacity in failing hearts. Am J Physiol Heart Circ Physiol 2003;285:H541-H548.
34. Lionetti V, Linke A, Chandler MP, Young ME, Penn MS, Gupte S et al. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res 2005;66:454-461.
35. Nojiri H, Shimizu T, Funakoshi M, Yamaguchi O, Zhou H, Kawakami S et al. Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem 2006;281:33789-33801.
36. Li YY, Maisch B, Rose ML, Hengstenberg C. Point mutations in mitochondrial DNA of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1997;29:2699-2709.
37. Dai L, Brookes PS, Darley-Usmar VM, Anderson PG. Bioenergetics in cardiac hypertrophy: mitochondrial respiration as a pathological target of NO. Am J Physiol Heart Circ Physiol 2001;281:H2261-H2269.
38. Moens ALMD, Takimoto EMDP, Tocchetti CGMDP, Chakir KP, Bedja DMS, Cormaci GMD et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008;117:2626-2636.
39. Porter RK. Mitochondrial proton leak: a role for uncoupling proteins 2 and 3? Biochim Biophys Acta 2001;1504:120-127.
40. Noma T, Nishiyama A, Mizushige K, Murakami K, Tsuji T, Kohno M et al. Possible role of uncoupling protein in regulation of myocardial energy metabolism in aortic regurgitation model rats. FASEB J 2001;15:1206-1208.
41. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004;364:1786-1788.
42. Razeghi P, Young ME, Cockrill TC, Frazier OH, Taegtmeyer H. Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. Circulation 2002;106:407-411.
43. Morgan EE, Chandler MP, Young ME, McElfresh TA, Kung TA, Rennison JH et al. Dissociation between gene and protein expression of metabolic enzymes in a rodent model of heart failure. Eur J Heart Fail 2006;8:687-693.
44. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters Wet al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997;96:2190-2196.
45. Shen W, Asai K, Uechi M, Mathier MA, Shannon RP, Vatner SF et al. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. Circulation 1999;100:2113-2118.
46. Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 2006;114:1151-1158.
47. Maslov MY, Chacko VP, Stuber M, Moens AL, Kass DA, Champion HC et al. Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice. Am J Physiol Heart Circ Physiol 2007;292:H387- H391.
48. Sochor H, Schelbert HR, Schwaiger M, Henze E, Phelps ME. Studies of fatty acid metabolism with positron emission tomography in patients with cardiomyopathy. Eur J Nucl Med 1986;12:S66-S69.
49. Tadamura E, Kudoh T, Hattori N, Inubushi M, Magata Y, Konishi J et al. Impairment of BMIPP uptake precedes abnormalities in oxygen and glucose metabolism in hypertrophic cardiomyopathy. J Nucl Med 1998;39:390-396.
50. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002;40:271- 277.
51. de las Fuentes L, Herrero P, Peterson LR, Kelly DP, Gropler RJ, Davila-Roman VG. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension 2003;41:83-87.
52. Grover-McKay M, Schwaiger M, Krivokapich J, Perloff JK, Phelps ME, Schelbert HR. Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1989;13:317-324.
53. Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994;43:174-179.
54. Lommi J, Kupari M, Yki-Järvinen H. Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol 1998;81:45-50.
55. Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and. J Nucl Med 2001;42:55-62.
56. Stolen KQ, Kemppainen J, Kalliokoski KK, Hällsten K, Luotolahti M, Karanko H et al. Myocardial perfusion reserve and oxidative metabolism contribute to exercise capacity in patients with dilated cardiomyopathy. J Card Fail 2004;10:132-140.
57. Uehara T, Ishida Y, Hayashida K, Shimonagata T, Miyake Y, Sago M et al. Myocardial glucose metabolism in patients with hypertrophic cardiomyopathy: assessment by F-18-FDG PET study. Ann Nucl Med 1998;12:95-103.
58. Tuunanen H, Engblom E, Naum A, Scheinin M, Någren K, Airaksinen J et al. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 2006;12:644-652.
59. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002;106:606-612.
60. Lei B, Lionetti V, Young ME, Chandler MP, d' Agostino C, Kang E et al. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 2004;36:567-576.
61. Christe ME, Rodgers RL. Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J Mol Cell Cardiol 1994;26:1371-1375.
62. El Alaoui-Talibi Z, Guendouz A, Moravec M, Moravec J. Control of oxidative metabolism in volume-overloaded rat hearts: effect of propionyl-L-carnitine. Am J Physiol 1997;272:H1615-H1624.
63. Akki A, Smith K, Seymour A-M. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol Cell Biochem 2008;311:215-224.
64. Pellieux C, Aasum E, Larsen TS, Montessuit C, Papageorgiou I, Pedrazzini T et al. Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway. J Mol Cell Cardiol 2006;41:459-466.
65. Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol 2004;287:H1538-H1543.
66. Remondino A, Rosenblatt-Velin N, Montessuit C, Tardy I, Papageorgiou I, Dorsaz PA et al. Altered expression of proteins of metabolic regulation during remodeling of the left ventricle after myocardial infarction. J Mol Cell Cardiol 2000;32:2025-2034.
67. de Brouwer KFJ, Degens H, Aartsen WM, Lindhout M, Bitsch NJJE, Gilde AJ et al. Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice. J Mol Cell Cardiol 2006;40:838-845.
68. Lydell CP, Chan A, Wambolt RB, Sambandam N, Parsons H, Bondy GP et al. Pyruvate dehydrogenase and the regulation of glucose oxidation in hypertrophied rat hearts. Cardiovasc Res 2002;53:841-851.
69. Tian R, Musi N, D'Agostino J, Hirshman MF, Goodyear LJ. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001;104:1664-1669.
70. Chess DJ, Lei B, Hoit BD, Azimzadeh AM, Stanley WC. Deleterious effects of sugar and protective effects of starch on cardiac remodeling, contractile dysfunction, and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 2007;293:H1853-H1860.
71. Lei B, Chess DJ, Keung W, O'Shea KM, Lopaschuk GD, Stanley WC. Transient activation of P38 MAP kinase and up-regulation of Pim-1 kinase in cardiac hypertrophy despite no activation of AMPK. J Mol Cell Cardiol 2008;45:404-410.
72. Kantor PF, Robertson MA, Coe JY, Lopaschuk GD. Volume overload hypertrophy of the newborn heart slows the maturation of enzymes involved in the regulation of fatty acid metabolism. J Am Coll Cardiol 1999;33:1724-1734.
73. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996;94:2837-2842.
74. Sack MN, Disch DL, Rockman HA, Kelly DP. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl Acad Sci USA 1997;94:6438-6443.
75. Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML et al. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 1998;4:1269-1275.
76. Rosenblatt-Velin N, Montessuit C, Papageorgiou I, Terrand J, Lerch R. Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism. Cardiovasc Res 2001;52:407-416.
77. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 2004;95:568-578.
78. Razeghi P, Young ME, Ying J, Depre C, Uray IP, Kolesar J et al. Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology 2002;97:203-209.
79. Schupp M, Kintscher U, Fielitz J, Thomas J, Pregla R, Hetzer R et al. Cardiac PPAR[alpha] expression in patients with dilated cardiomyopathy. Eur J Heart Fail 2006;8:290-294.
80. Guertl B, Noehammer CGH. Metabolic cardiomyopathies. Int J Exp Pathol 2000;81:349-372.
81. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ et al. Peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 2003;92:518- 524.
82. Huss JM, Imahashi K-i, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A et al. The Nuclear Receptor ERR[alpha] Is Required for the Bioenergetic and Functional Adaptation to Cardiac Pressure Overload. Cell Metabolism 2007;6:25-37.
83. ATP channel subunits and energy metabolism. Circ Res 2008;102:e20-e35.
84. Kelly DP, Strauss AW. Inherited cardiomyopathies. New Eng J Med 1994;330:913-919.
85. Exil VJ, Roberts RL, Sims H, McLaughlin JE, Malkin RA, Gardner CD et al. Very-long-chain acyl-Coenzyme A dehydrogenase deficiency in mice. Circ Res 2003;93:448-455.
86. Hansson A, Hance N, Dufour E, Rantanen A, Hultenby K, Clayton DA et al. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc Natl Acad Sci USA 2004;101:3136-3141.
87. Sebastiani M, Giordano C, Nediani C, Travaglini C, Borchi E, Zani M et al. Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies. J Am Coll Cardiol 2007;50:1362- 1369.
88. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L et al. Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280-3288.
89. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation Inhibitor, in patients with heart failure. J Am Coll Cardiol 2006;48:992-998.
90. Brigadeau FMD, Gele PP, Wibaux MMD, Marquie CMD, Martin-Nizard FP, Torpier GP et al. The PPAR[alpha] activator Fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-Induced cardiomyopathy. J Cardiovasc Pharmacol 2007;49:408-415.
91. Xu KY, Zweier JL, Becker LC. Functional coupling between glycolysis and sarcoplasmic reticulum calcium transport. Circ Res 1995;77:88-97.
92. 2+ release in cat ventricular myocytes. J Physiol 2006;577:281-293.
93. 2+ signaling in bovine vascular endothelial cells. Am J Physiol Cell Physiol 2007;293:C106-C118.
94. Dhar-Chowdhury P, Malester B, Rajacic P, Coetzee W. The regulation of ion channels and transporters by glycolytically derived ATP. Cell Mol Life Sci 2007;64:3069-3083.
95. Morgan EE, Rennison JH, Young ME, McElfresh TA, Kung TA, Tserng K-Y et al. Effects of chronic activation of peroxisome proliferator-activated receptor-(alpha) or high-fat feeding in a rat infarct model of heart failure. Am J Physiol Heart Circ Physiol 2006;290:H1899-H1904.
96. Liao R, Jain M, Cui L, D'Agostino J, Aiello F, Luptak I et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 2002;106:2125-2131.
97. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006;27:942-948.
98. Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002;27:621-636.
99. Smeets PJ, Teunissen BEJ, Planavila A, de Vogel-van den Bosch H, Willemsen PHM, van der Vusse GJ et al. Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by PPARalpha and PPARdelta. J Biol Chem 2008;283:29109-29118.
100. MacInnes A, Fairman DA, Binding P, Rhodes JA, Wyatt MJ, Phelan A et al. The antianginal agent trimetazidine does not exert Its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl Coenzyme A thiolase. Circ Res 2003;93:e26-e32.
101. Saeedi R, Grist M, Wambolt RB, Bescond-Jacquet A, Lucien A, Allard MF. Trimetazidine normalizes postischemic function of hypertrophied rat hearts. J Pharmacol Exp Ther 2005;314:446-454.